Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

William U. Shipley, Wendy Seiferheld, Himanshu Lukka, +19

New England Journal of Medicine

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial

Alan Pollack, Theodore Karrison, Alexander G. Balogh, +19

The Lancet

UrologyRadiation MedicineRadiation TherapyMedicineAndrogen Deprivation Therapy +5

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

Andre Esteva, Jean Feng, Douwe van der Wal, +42

npj Digital Medicine

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial

Seth A. Rosenthal, Chen Hu, Oliver Sartor, +18

Journal of Clinical Oncology

Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910

Thomas M. Pisansky, Daniel Hunt, Leonard G. Gomella, +13

Journal of Clinical Oncology

A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).

Howard M. Sandler, Chen Hu, Seth A. Rosenthal, +17

Journal of Clinical Oncology

Cancer ManagementAndrogen SuppressionPhase Iii ProtocolRadiation MedicineOncology +16

Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601

Will Jackson, Ming Tang, Matthew J. Schipper, +16

Journal of Clinical Oncology

A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).

Howard M. Sandler, Chen Hu, Seth A. Rosenthal, +17

Journal of Clinical Oncology

UrologyGenitourinary CancerMalignant DiseaseMedicineCancer Management +13

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial

Oliver Sartor, Theodore Karrison, Howard M. Sandler, +17

European Urology

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408

R.C. Nichols, Chen Hu, Jean-Paul Bahary, +12

Advances in Radiation Oncology